1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Anorexia Nervosa – Pipeline Review, H1 2013

Anorexia Nervosa – Pipeline Review, H1 2013

  • March 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Anorexia Nervosa – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Anorexia Nervosa - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anorexia Nervosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anorexia Nervosa. Anorexia Nervosa - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anorexia Nervosa.
- A review of the Anorexia Nervosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Anorexia Nervosa pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Anorexia Nervosa.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Anorexia Nervosa pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Anorexia Nervosa - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Anorexia Nervosa Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Anorexia Nervosa 7
Anorexia Nervosa Therapeutics under Development by Companies 9
Anorexia Nervosa Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Anorexia Nervosa Therapeutics - Products under Development by Companies 14
Anorexia Nervosa Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Anorexia Nervosa Therapeutics Development 16
KangLaiTe USA 16
Rhythm Pharmaceuticals 17
Anorexia Nervosa - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
RM-131 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Kanglaite - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
aripiprazole - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
oxytocin - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Dehydroepiandrosterone + Hormone Replacement Therapy - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Anorexia Nervosa Therapeutics - Drug Profile Updates 31
Anorexia Nervosa Therapeutics - Discontinued Products 32
Anorexia Nervosa - Product Development Milestones 33
Featured News and Press Releases 33
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 33
Apr 26, 2007: Sapphire Therapeutics, Inc. to Present Results From Anamorelin Phase II Cachexia/Anorexia Studies at American Society of Clinical Oncology and Endocrine Society Annual Meetings in June 33
Dec 15, 2005: Sapphire Therapeutics, Inc.'s Oral Ghrelin Mimetic Shows Potential for Treating Cancer Anorexia/Cachexia 33
Jan 10, 2005: Rejuvenon's RC-1291 Ghrelin Mimetic Receives Fast Track Designation From FDA for Cancer Anorexia/Cachexia 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products Under Development for Anorexia Nervosa, H1 2013 7
Products under Development for Anorexia Nervosa - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
KangLaiTe USA, H1 2013 16
Rhythm Pharmaceuticals, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Anorexia Nervosa Therapeutics - Drug Profile Updates 31
Anorexia Nervosa Therapeutics - Discontinued Products 32



List of Figures

Number of Products under Development for Anorexia Nervosa, H1 2013 7
Products under Development for Anorexia Nervosa - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Binge Eating Disorder - Pipeline Review, H2 2016

Binge Eating Disorder - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Binge Eating Disorder - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2016, provides an ...

Binge Eating Disorder - Pipeline Review, H1 2016

Binge Eating Disorder - Pipeline Review, H1 2016

  • $ 2000
  • Company report
  • April 2016
  • by Global Markets Direct

Binge Eating Disorder - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Binge Eating Disorder - Pipeline Review, H1 2016’, provides an overview of the Binge Eating Disorder pipeline landscape. ...

Binge Eating Disorder Global Clinical Trials Review, H2, 2015

Binge Eating Disorder Global Clinical Trials Review, H2, 2015

  • $ 2500
  • Company report
  • December 2015
  • by Global Data

Binge Eating Disorder Global Clinical Trials Review, H2, 2015 Summary GlobalData's clinical trial report, “Binge Eating Disorder Global Clinical Trials Review, H2, 2015" provides an overview of Binge ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.